Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-12-10
DOI
10.1038/s41416-020-01201-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Potential of Nintedanib in Treatment of Progressive Fibrosing Interstitial Lung Diseases
- (2019) Lutz Wollin et al. EUROPEAN RESPIRATORY JOURNAL
- Cancer-associated fibroblasts in desmoplastic tumors: emerging role of integrins
- (2019) Cédric Zeltz et al. SEMINARS IN CANCER BIOLOGY
- MA05.11 Safety and Efficacy of Nintedanib in Combination with Pembrolizumab in Patients with Refractory/Relapsing Malignant Pleural Mesothelioma
- (2019) A. Varga et al. Journal of Thoracic Oncology
- P2.01-06 Phase I Study of Nivolumab and Ipilimumab Combined with Nintedanib in Advanced Non-Small Cell Lung Cancer
- (2019) S. Puri et al. Journal of Thoracic Oncology
- U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation
- (2019) Koji Haratani et al. JOURNAL OF CLINICAL INVESTIGATION
- Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer
- (2018) Ana Costa et al. CANCER CELL
- Safety and efficacy results from a phase I dose-escalation trial of Nintedanib in combination with Pembrolizumab in patients with advanced solid tumors (PEMBIB trial).
- (2018) Andreea Varga et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer
- (2018) Satomi Watanabe et al. CANCER SCIENCE
- Turning foes to friends: targeting cancer-associated fibroblasts
- (2018) Xueman Chen et al. NATURE REVIEWS DRUG DISCOVERY
- The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC
- (2017) Christian Manegold et al. Journal of Thoracic Oncology
- Tyrosine kinase inhibitor BIBF1120 ameliorates inflammation, angiogenesis and fibrosis in CCl4-induced liver fibrogenesis mouse model
- (2017) Büsra Öztürk Akcora et al. Scientific Reports
- FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via STAT3–CCL2 Signaling
- (2016) Xuguang Yang et al. CANCER RESEARCH
- Selective Activation of Anticancer Chemotherapy by Cancer-Associated Fibroblasts in the Tumor Microenvironment
- (2016) Mi-Gyeong Kim et al. JNCI-Journal of the National Cancer Institute
- Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression
- (2016) Hanane Laklai et al. NATURE MEDICINE
- Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
- (2016) Jeffrey J. Wallin et al. Nature Communications
- Selective Activation of Anticancer Chemotherapy by Cancer-Associated Fibroblasts in the Tumor Microenvironment
- (2016) Mi-Gyeong Kim et al. JNCI-Journal of the National Cancer Institute
- Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis
- (2015) Jingang Huang et al. ANNALS OF THE RHEUMATIC DISEASES
- Dasatinib inhibits TGFβ-induced myofibroblast differentiation through Src-SRF Pathway
- (2015) Maha Abdalla et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
- (2015) Lutz Wollin et al. EUROPEAN RESPIRATORY JOURNAL
- Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy
- (2015) Rosa Barreira da Silva et al. NATURE IMMUNOLOGY
- FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies
- (2014) M. W. Wynes et al. CLINICAL CANCER RESEARCH
- Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
- (2014) Martin Reck et al. LANCET ONCOLOGY
- Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
- (2014) Luca Richeldi et al. NEW ENGLAND JOURNAL OF MEDICINE
- BIBF 1120 (Nintedanib), a Triple Angiokinase Inhibitor, Induces Hypoxia but not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer
- (2013) B. Kutluk Cenik et al. MOLECULAR CANCER THERAPEUTICS
- The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer
- (2013) H Hayashi et al. ONCOGENE
- Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
- (2013) C. Feig et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mutant Soluble Ectodomain of Fibroblast Growth Factor Receptor-2 IIIc Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice
- (2012) Zhi-hong Yu et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Mechanisms of fibrosis: therapeutic translation for fibrotic disease
- (2012) Thomas A Wynn et al. NATURE MEDICINE
- Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
- (2011) K. Yonesaka et al. Science Translational Medicine
- Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice
- (2009) Angélica M. Santos et al. JOURNAL OF CLINICAL INVESTIGATION
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now